Cilostazol This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This page shows you the latest news and research items in this category.
Increased expression of ATP-binding cassette transporter A1 (ABCA1) as a possible mechanism for the protective effect of cilostazol against hepatic steatosis
Cilostazol, a phosphodiesterase 3, has been widely used in patients with arterial disease and is known to have additional beneficial effects on dyslipidemia. However, the effect of cilostazol on hepatic steatosis has not been fully elucidated. We investigated the effect of cilostazol on hepatic ABCA1 expression and hepatic steatosis in diet-induced obesity mice model. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - July 24, 2015 Category: Biomedical Science Authors: Byung Hun Jeon, Yong-ho Lee, Mi Ra Yun, Soo Hyun Kim, Byung Wan Lee, Eun Seok Kang, Hyun Chul Lee, Bong-Soo Cha Source Type: research
Intimal exfoliation Following Abnormal Circular Proliferation as a Cause for Acute Coronary Syndrome in a Patient with Polycythemia Vera
A 78-year-old female with a history of polycythemia vera (PV) was admitted due to sudden severe chest pain at rest. She had been treated with 500mg/day of hydroxycarbamide for PV (platelet counts ranging from 480,000 to 600,000/μl, leukocyte counts ranging from 14,500 to 18,000/μl, and hematocrit levels ranging from 37 to 42 %), and 100mg/day of cilostazol for previous cerebral transient ischemia attack. Physical examination revealed no specific findings except splenomegaly. Anterior ST-segment elevation myocardial infarction (STEMI) was diagnosed by electrocardiography. (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - July 19, 2015 Category: Cardiology Authors: Tsuyoshi Nishiguchi, Atsushi Tanaka, Takashi Yamano, Takashi Kubo, Takashi Akasaka Source Type: research
Protective effect of cilostazol on doxorubicin-induced cardiomyopathy in mice.
Abstract Doxorubicin (Dox) is an effective anti-cancer drug, but its use is limited due to the adverse effect by inducing the irreversible dilated cardiomyopathy. Cilostazol (Cilo), a potent phosphodiesterase III inhibitor, has been reported to have an anti-inflammatory effect. Here, we investigated whether Cilo has a protective effect on Dox-induced cardiomyopathy (DIC). The mice were randomly divided into four groups: saline-control, Dox (15mg/kg), Dox (15mg/kg) plus Cilo (50mg/kg), and Cilo (50mg/kg). As results, the co-administration of Dox and Cilo significantly enhanced the left ventricular systolic function ...
Source: Free Radical Biology and Medicine - July 18, 2015 Category: Biology Authors: Sin Koh J, Yi CO, Won Heo R, Ahn JW, Rang Park J, Eun Lee J, Kim JH, Hwang JY, Seob Roh G Tags: Free Radic Biol Med Source Type: research
Cilostazol, Not Aspirin, Prevents Stenosis of Bioresorbable Vascular Grafts in a Venous Model.
CONCLUSIONS: Cilostazol prevents stenosis of bioresorbable vascular graft in a mouse inferior vena cava implantation model up to 24 weeks and is accompanied by reduction of smooth muscle cell proliferation and acute inflammation. PMID: 26183618 [PubMed - as supplied by publisher] (Source: Arteriosclerosis, Thrombosis and Vascular Biology)
Source: Arteriosclerosis, Thrombosis and Vascular Biology - July 16, 2015 Category: Cardiology Authors: Tara S, Kurobe H, de Dios Ruiz Rosado J, Best CA, Shoji T, Mahler N, Yi T, Lee YU, Sugiura T, Hibino N, Partida-Sanchez S, Breuer CK, Shinoka T Tags: Arterioscler Thromb Vasc Biol Source Type: research
New therapeutic effects of cilostazol in patients with ischemic disorders.
The objective of the present review is to analyze the existing data about the therapeutic effects of CIL, with the purpose of providing practical indications about this topic for the management of subjects affected by ischemic disorders. PMID: 26156267 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - July 11, 2015 Category: Drugs & Pharmacology Authors: Biscetti F, Ferraccioli G, Flex A Tags: Curr Vasc Pharmacol Source Type: research
Understanding the role of antioxidant therapy for intermittent claudication; Good, bad, or both?
Abstract Peripheral arterial disease (PAD) is a global health issue, affecting 202 million people worldwide. The most common symptom of PAD is intermittent claudication (IC), which is associated with increased risk of cardiovascular morbidity and mortality, and thus is an area where new therapies are urgently needed. Currently the only FDA-approved medications for treating PAD-associated walking impairment are pentoxifylline and cilostazol. However, these agents have been shown to produce only minimal improvement in maximal treadmill walking distance. Much evidence exists for a role of oxidant stress and inflammati...
Source: American Journal of Physiology. Heart and Circulatory Physiology - July 10, 2015 Category: Physiology Authors: Miller SJ, Unthank JL Tags: Am J Physiol Heart Circ Physiol Source Type: research
Stimulation of angiogenesis by cilostazol accelerates fracture healing in mice
This article is protected by copyright. All rights reserved (Source: Journal of Orthopaedic Research)
Source: Journal of Orthopaedic Research - July 1, 2015 Category: Orthopaedics Authors: Steven C. Herath, Thorsten Lion, Moritz Klein, David Stenger, Claudia Scheuer, Jörg H. Holstein, Philipp Mörsdorf, Mika F.R. Rollmann, Tim Pohlemann, Michael D. Menger, Tina Histing Tags: Research Article Source Type: research
Cilostazol attenuates murine hepatic ischemia and reperfusion injury via heme oxygenase-dependent activation of mitochondrial biogenesis
Hepatic ischemia-reperfusion (I/R) can cause hepatocellular injury associated with the inflammatory response and mitochondrial dysfunction. We studied the protective effects of the phosphodiesterase inhibitor cilostazol in hepatic I/R and the roles of mitochondria and the Nrf2/heme oxygenase-1 (HO-1) system. Wild-type, Hmox1–/–, or Nrf2–/– mice were subjected to hepatic I/R in the absence or presence of cilostazol followed by measurements of liver injury. Primary hepatocytes were subjected to cilostazol with the HO-1 inhibitor ZnPP, or Nrf2-specific siRNA, followed by assessment of mitochondrial bio...
Source: AJP: Gastrointestinal and Liver Physiology - July 1, 2015 Category: Gastroenterology Authors: Joe, Y., Zheng, M., Kim, H. J., Uddin, M. J., Kim, S.-K., Chen, Y., Park, J., Cho, G. J., Ryter, S. W., Chung, H. T. Tags: LIVER AND BILIARY TRACT Source Type: research
Efficacy of cilostazol for the treatment of Raynaud’s phenomenon in systemic sclerosis patients
Abstract Cilostazol is a selective inhibitor of phosphodiesterase-III with antiplatelet, antithrombotic and vasodilating properties. The aim of our study was to evaluate the effect of the drug on vasculopathy and Raynaud’s phenomenon (RP), in a series of patients with systemic sclerosis (SSc), before and after cilostazol treatment. Twenty-one consecutive SSc patients with moderate or severe RP were enrolled in an open-label study. Cilostazol was administered at the dose of 100 mg twice a day, for 12 months. Evaluations included: daily RP attack diary documenting the frequency and duration of RP episodes, H...
Source: Clinical and Experimental Medicine - June 19, 2015 Category: Research Source Type: research
Can crystal engineering be as beneficial as micronisation and overcome its pitfalls?: A case study with cilostazol
In conclusion, crystal engineering by habit modification show potential for dissolution enhancement with an added advantage of improved flow properties over micronization technique, for poorly soluble drugs like cilostazol. Graphical abstract (Source: International Journal of Pharmaceutics)
Source: International Journal of Pharmaceutics - June 18, 2015 Category: Drugs & Pharmacology Source Type: research
Cilostazol inhibits HMGB1 release in LPS-activated RAW 264.7 cells and increases the survival of septic mice
Inflammation and coagulation play important roles in the pathogenesis of sepsis. Anticoagulants with anti-inflammatory action draw attention as therapeutic agent in sepsis. (Source: Thrombosis Research)
Source: Thrombosis Research - June 15, 2015 Category: Hematology Authors: Ki Churl Chang Source Type: research
Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease.
CONCLUSIONS: Cilostazol administration improves long-term clinical outcomes including prevention of MACE and stroke after endovascular therapy in HD patients with PAD. PMID: 26074442 [PubMed - as supplied by publisher] (Source: Journal of Cardiology)
Source: Journal of Cardiology - June 11, 2015 Category: Cardiology Authors: Ishii H, Aoyama T, Takahashi H, Kumada Y, Kamoi D, Sakakibara T, Umemoto N, Suzuki S, Tanaka A, Ito Y, Murohara T Tags: J Cardiol Source Type: research
Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial
DiscussionPreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage is the largest secondary stroke prevention trial for informing antiplatelet therapy and lipid management in patients at high risk of haemorrhagic stroke. (Source: International Journal of Stroke)
Source: International Journal of Stroke - June 4, 2015 Category: Neurology Authors: Keun‐Sik Hong, Bum Joon Kim, Jun‐Young Lee, Sun U. Kwon, Tags: Protocol Source Type: research
Efficacy of Cilostazol a selective phosphodiesterase-3 inhibitor in rat model of Streptozotocin diabetes induced vascular dementia
Publication date: August 2015 Source:Pharmacology Biochemistry and Behavior, Volume 135 Author(s): Ashwani Kumar , Amit Kumar , Amteshwar S. Jaggi , Nirmal Singh The present study has been designed to investigate the potential of Cilostazol a phosphodiesterase-3 (PDE-3) inhibitor in diabetes-induced vascular dementia (Vad) employing Wistar rats. A single dose of Streptozotocin (STZ) was used for the induction of diabetes and subsequent Vad in rats. Memory and learning abilities of rats were evaluated with Morris water maze (MWM) test. Serum glucose, body weight, vascular endothelial function, serum nitrite/nitrate levels...
Source: Pharmacology Biochemistry and Behavior - May 31, 2015 Category: Biochemistry Source Type: research
Use of Whole Exome Sequencing for the Identification of Ito-Based Arrhythmia Mechanism and Therapy [Molecular Cardiology]
Conclusions We describe a novel arrhythmia mechanism and therapeutic approach to ameliorate the disease. Specifically, we identify the first coding variant of DPP6 in human ventricular fibrillation. These findings illustrate the power of genetic approaches for the elucidation and treatment of disease when carefully integrated with clinical and basic/translational research teams. (Source: JAHA:Journal of the American Heart Association)
Source: JAHA:Journal of the American Heart Association - May 26, 2015 Category: Cardiology Authors: Sturm, A. C., Kline, C. F., Glynn, P., Johnson, B. L., Curran, J., Kilic, A., Higgins, R. S. D., Binkley, P. F., Janssen, P. M. L., Weiss, R., Raman, S. V., Fowler, S. J., Priori, S. G., Hund, T. J., Carnes, C. A., Mohler, P. J. Tags: Molecular Cardiology Source Type: research
Cilostazol Bridges Surgical DES Patients Without DAPTCilostazol Bridges Surgical DES Patients Without DAPT
Based on long-term follow-up in an observational study, the PDE-3 inhibitor was called an "ingenious bridge" for patients taken off standard dual-antiplatelet therapy during surgery. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 11, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
Cilostazol Attenuates Murine Hepatic Ischemia and Reperfusion Injury via Heme Oxygenase-Dependent Activation of Mitochondrial Biogenesis.
Abstract Hepatic ischemia/reperfusion (I/R) can cause hepatocellular injury associated with the inflammatory response and mitochondrial dysfunction. We studied the protective effects of the phosphodiesterase inhibitor cilostazol in hepatic I/R, and the roles of mitochondria, and the Nrf2/ heme oxygenase-1 (HO-1) system. Wild type, Hmox1(-/-) or Nrf2(-/-) mice were subjected to hepatic I/R in the absence or presence of cilostazol followed by measurements of liver injury. HepG2 cells were subjected to cilostazol with the HO-1 inhibitor ZnPP, or Nrf2 specific siRNA, followed by assessment of mitochondrial biogenesis. ...
Source: Am J Physiol Gastroi... - May 7, 2015 Category: Gastroenterology Authors: Joe Y, Zheng M, Kim HJ, Uddin MJ, Kim SK, Chen Y, Park J, Cho GJ, Ryter SW, Chung HT Tags: Am J Physiol Gastrointest Liver Physiol Source Type: research
CILOSTAZOL Tablet [Golden State Medical Supply, Inc.]
Updated Date: May 5, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - May 5, 2015 Category: Drugs & Pharmacology Source Type: news
Cilostazol improves hepatic blood perfusion, microcirculation, and liver regeneration after major hepatectomy in rats
In conclusion, cilostazol increases hepatic blood perfusion, microcirculation, and liver regeneration after a major hepatectomy. Thus, cilostazol may represent a novel strategy to reduce the rate of liver failure after both extended hepatectomy and small‐for‐size liver transplantation. Liver Transpl, 2015. © 2015 AASLD. (Source: Liver Transplantation)
Source: Liver Transplantation - May 4, 2015 Category: Transplant Surgery Authors: Maximilian von Heesen, Stefan Dold, Simon Müller, Claudia Scheuer, Otto Kollmar, Martin K. Schilling, Michael D. Menger, Mohammed R. Moussavian Tags: Original Article Source Type: research
An experimental study of the effect of pre-operative administration of cilostazol on random skin flap survival in rats: double blinded randomized controlled trial
Background: Insufficient arterial blood flow is the one cause of flap necrosis. Cilostazol is an inhibitor of phosphodiesterase III and increases cyclic AMP level in vascular smooth muscle cell causing vasodilation. Therefore, effect of cilostazol is expected to improve the viability of the flap. Methods: Double blinded randomized controlled trial was conducted. The study was to compare the survival of dorsal rat flaps between preoperative cilostazol supplemented diet and regular diet. The flap survival area was measured using PixArea Image software on post operative day 1,3,5 and 7. Fluorescein injection was performed to ...
Source: BioMed Central - April 28, 2015 Category: Journals (General) Authors: Chairat BurusapatJanjira PaengnoiKantang Satayasoontorn Source Type: research
When Should Cilostazol (Pletal) and Dipyridamole Be Discontinued Before Neuroaxial Block?
No abstract available (Source: Regional Anesthesia and Pain Medicine)
Source: Regional Anesthesia and Pain Medicine - April 24, 2015 Category: Anesthesiology Tags: Letters to the Editor Source Type: research
Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation, Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study
Despite established clinical efficacy of dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor in acute coronary syndrome (ACS) patients, persistent recurrent ischemic event (~10% during 1year) suggests a ceiling effect in attenuating ischemic events and some clinical events are mediated by other pathways . Cilostazol is a unique dual inhibitor of phosphodiesterase 3 (PDE3) and adenosine reuptake . It also provides vasodilation, enhances endothelial function, inhibits neointimal hyperplasia and in-stent restenosis, decreases various inflammatory pathways, improves lipid profile, and has cardiop...
Source: International Journal of Cardiology - April 23, 2015 Category: Cardiology Authors: Kyounghoon Lee, Sang-Yong Yoo, Jon Suh, Keun Ho Park, Yongwhi Park, Udaya S. Tantry, Ki-Soo Park, Seung Hwan Han, Woong Chol Kang, Dae-Hee Shin, Changkun Lee, Si Wan Choi, Jae-Hwan Lee, Yoon Haeng Cho, Nae-Hee Lee, Myung Ho Jeong, Youngkeun Ahn, Jacek Kub Tags: Letter to the editor Source Type: research
Improvement in in vitro fertilization outcome following in vivo synchronization of oocyte maturation in mice
This study was therefore designed to define the effect of in vivo synchronization of oocyte maturation on IVF rates. Mice were superovulated and orally treated with 7.5 mg cilostazol (CLZ), a phosphodiesterase 3A (PDE3A) inhibitor, to induce ovulation of immature oocytes at different stages depending on frequency and time of administration of CLZ. Mice treated with CLZ ovulated germinal vesicle (GV) or metaphase I (MI) oocytes that underwent maturation in vitro or in vivo (i.e. in the oviduct) followed by IVF. Superovulated control mice ovulated mature oocytes that underwent IVF directly upon collection. Ovu...
Source: Experimental Biology and Medicine - April 15, 2015 Category: Research Authors: Taiyeb, A. M., Muhsen-Alanssari, S. A., Dees, W., Ridha-Albarzanchi, M. T., Kraemer, D. C. Tags: Pharmacology/Toxicology Source Type: research
Serum uric acid is positively associated with cerebral white matter hyperintensities in patients with acute lacunar infarction: Subgroup analysis of the Effect of Cilostazol in Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler (ECLIPse) study (P1.046)
CONCLUSIONS: This study showed that WMH volume was positively associated with serum UA in patients with acute lacunar infarction. Our findings indicate that impaired cerebrovascular hemodynamics may be associated with cerebral WMH. Study Supported by: NoneDisclosure: Dr. Han has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Park has nothing to disclose. Dr. Park has nothing to disclose. (Source: Neurology)
Source: Neurology - April 8, 2015 Category: Neurology Authors: Han, S. W., Lee, J. Y., Lee, K.-Y., Park, J. H., Park, J. H. Tags: Cerebrovascular Disease and Interventional Neurology: The Spectrum of Small Vessel Cerebrovascular Disease Source Type: research
CILOSTAZOL Tablet [Golden State Medical Supply, Inc.]
Updated Date: Mar 30, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - March 30, 2015 Category: Drugs & Pharmacology Source Type: news
Preconditioning by Cilostazol Protects against Cold Hepatic Ischemia-Reperfusion Injury.
Conclusions Inhibition of PDE3 reduces endothelial cell activation and hepatocellular injury in cold ischemia/reperfusion of the liver. PMID: 25811412 [PubMed - as supplied by publisher] (Source: Annals of Transplantation)
Source: Annals of Transplantation - March 27, 2015 Category: Transplant Surgery Authors: von Heesen M, Müller S, Keppler U, Strowitzki MJ, Scheuer C, Schilling MK, Menger MD, Moussavian MR Tags: Ann Transplant Source Type: research
Retraction Note: Systematic study of cilostazol on secondary stroke prevention: a meta-analysis
(Source: European Journal of Medical Research)
Source: European Journal of Medical Research - March 26, 2015 Category: Research Source Type: research
Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.
CONCLUSIONS: Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. This could be a novel strategy for cardioembolic stroke prevention potentially by affecting cardiac remodelling, in contrast to secondary anticoagulant therapy. PMID: 25798683 [PubMed - as supplied by publisher] (Source: Neurological Research)
Source: Neurological Research - March 24, 2015 Category: Neurology Tags: Neurol Res Source Type: research
Efficacy and Safety of Cilostazol Therapy in Ischemic Stroke: A Meta-analysis
Antiplatelet therapy is recommended for patients who have experienced ischemic stroke. We performed a meta-analysis to compare the efficacy and safety of cilostazol with other antiplatelet therapies in patients with ischemic stroke. (Source: Journal of Stroke and Cerebrovascular Diseases)
Source: Journal of Stroke and Cerebrovascular Diseases - March 24, 2015 Category: Neurology Authors: Liang Tan, Barnhart Margaret, John H. Zhang, Rong Hu, Yi Yin, Liu Cao, Hua Feng, Yanqi Zhang Source Type: research
Optimal- vs. standard-antiplatelet therapy on platelet function and long-term clinical outcomes in patients with high on-treatment platelet reactivity: 2-year outcomes of the multicentre, randomized Optimal-antiPlatelet Therapy (OPT) trial
Optimal strategy for the management of high on-treatment platelet reactivity (HPR), an independent predictor of ischaemic events, is not yet clear. The aim of this study was to explore the safety and efficacy of personalized antiplatelet therapy based on platelet function testing in patients with HPR. A total of 840 patients with HPR who underwent coronary stenting for acute coronary syndrome (ACS) were randomly assigned in a 1:2 ratio to receive standard dual-antiplatelet therapy (n = 280) or platelet function-guided optimal-antiplatelet therapy (n = 560). In the optimal group, patients initially received clopidogrel 150 ...
Source: European Journal of Heart Failure Supplements - March 23, 2015 Category: Cardiology Authors: Li, Y., Han, Y., Guan, S., Sun, Y., Guo, L., Yang, B., Zang, H., Jing, Q., Wang, X., Ma, Y., Liu, X., Li, J., Zheng, L. Tags: Articles Source Type: research
Efficacy of Antiplatelet Therapy in Secondary Prevention Following Lacunar Stroke: Pooled Analysis of Randomized Trials [Clinical Sciences]
Conclusions— Our results suggest that any of the single antiplatelet agents compared with placebo in the included trials is adequate for secondary stroke prevention after lacunar stroke. Dual antiplatelet therapy should not be used for long-term stroke prevention in this stroke subtype. (Source: Stroke)
Source: Stroke - March 23, 2015 Category: Neurology Authors: Kwok, C. S., Shoamanesh, A., Copley, H. C., Myint, P. K., Loke, Y. K., Benavente, O. R. Tags: Antiplatelets Clinical Sciences Source Type: research
CILOSTAZOL Tablet [Apotex Corp.]
Updated Date: Mar 13, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - March 13, 2015 Category: Drugs & Pharmacology Source Type: news
Acute myocardial infarction after cilostazol use in a patient with systemic lupus erythematosus
Anaphylaxis is a life-threatening allergic reaction that is rapid in onset and which can cause sudden death. Kounis syndrome (KS) is the concurrence of acute coronary syndromes combined with allergic or hypersensitivity and anaphylactic reactions . Cilostazol is a medication for the treatment of intermittent claudication , but which can enhance allergic complications . Herein, we describe a case of cilostazol-induced KS in a 66-year-old female with systemic lupus erythematosus (SLE). (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - March 11, 2015 Category: Cardiology Authors: Jincheng Guo, Wenming Chen, Guozhong Wang, Fuli Zhu Tags: Letter to the editor Source Type: research
Clinical Efficacy and Safety of Cilostazol: A Critical Review of the Literature
Abstract Cilostazol is a unique antiplatelet agent that has been commercially available for over two decades. As a phosphodiesterase III inhibitor, it reversibly inhibits platelet aggregation yet also possesses vasodilatory and antiproliferative properties. It has been widely studied in a variety of disease states, including peripheral arterial disease, cerebrovascular disease, and coronary artery disease with percutaneous coronary intervention. Overall, cilostazol appears to be a promising agent in the management of these disease states with a bleeding profile comparable to placebo; even when combined with other ...
Source: Drugs - March 10, 2015 Category: Drugs & Pharmacology Source Type: research
Intervention or Exercise? The Answer Is Yes! ∗
Intermittent claudication is the most common symptomatic form of peripheral artery disease (PAD). The magnitude of the disability from claudication is severe, such that patients report a marked decrease in their quality of life (1). Despite vigorous investigative efforts, only 4 treatments reliably reduce disability and increase walking distance: cilostazol; exercise training; percutaneous angioplasty and stenting; and surgical bypass. Cilostazol, an oral phosphodiesterase-3 inhibitor, modestly increases walking distance and rarely returns patients to full functional status (2). Therapies currently recommended most to reli...
Source: Journal of the American College of Cardiology - March 9, 2015 Category: Cardiology Source Type: research
CILOSTAZOL Tablet [Roxane Laboratories, Inc]
Updated Date: Mar 5, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - March 5, 2015 Category: Drugs & Pharmacology Source Type: news
Cilostazol induces vasodilation through the activation of Ca(2+)-activated K(+) channels in aortic smooth muscle.
Abstract We investigated the vasorelaxant effect of cilostazol and related signaling pathways in phenylephrine (Phe)-induced pre-contracted aortic rings. Cilostazol induced vasorelaxation in a concentration-dependent manner when aortic rings were pre-contracted with Phe. Application of the voltage-dependent K(+) (Kv) channel inhibitor 4-AP, the ATP-sensitive K(+) (KATP) channel inhibitor glibenclamide, and the inwardly rectifying K(+) (Kir) channel inhibitor Ba(2+) did not alter the vasorelaxant effect of cilostazol; however, pre- and post-treatment with the big-conductance Ca(2+)-activated K(+) (BKCa) channel inhi...
Source: Vascular Pharmacology - March 5, 2015 Category: Drugs & Pharmacology Authors: Li H, Hong DH, Son YK, Na SH, Jung WK, Bae YM, Seo EY, Kim SJ, Choi IW, Park WS Tags: Vascul Pharmacol Source Type: research
Cilostazol research in Asia: can it be applied to European and American patients?
Cilostazol is an antiplatelet drug often used in Asian countries like Korea, Japan, and China. However, it is rarely used in the west. Cilostazol inhibits phosphodiesterase, increases cyclic AMP concentrations, and consequently inhibits platelet aggregation. Interestingly, it also has vasodilatory activity, inhibits vascular smooth muscle proliferation, and protects the endothelium. Studies in Asia have shown that cilostazol is effective in the secondary prevention of stroke. Moreover, it is significantly less likely to cause bleeding complications than aspirin. Additional trials have shown that cilostazol is effective in ...
Source: International Journal of Stroke - March 4, 2015 Category: Neurology Authors: Jong S. Kim, Sun U. Kwon, Shinichiro Uchiyama Tags: Leading Opinion (Invited) Source Type: research
Hemichorea in a diabetes mellitus patient following acute ischemic stroke with changes in regional cerebral blood flow
Publication date: Available online 4 March 2015 Source:Journal of the Chinese Medical Association Author(s): Yutaka Suzuki , Minoru Oishi , Akira Kanno , Katsuhiko Ogawa , Mariko Fujisawa , Satoshi Kamei It is not unusual to observe hemichorea in patients with diabetes mellitus, with origins attributable to recent ischemia. Our patient was a 66-year-old female with diabetes mellitus who suddenly developed right hemichorea, mild muscle weakness of the right upper extremity, ideational apraxia, and acalculia. Her blood glucose was 600 mg/dL, and HbA1c was 13.3%. After the patient underwent head magnetic resonance imaging ...
Source: Journal of the Chinese Medical Association - March 4, 2015 Category: Journals (General) Source Type: research
Cilostazol improves hepatic blood perfusion, microcirculation and liver regeneration after major hepatectomy in rats
Conclusion: Cilostazol increases hepatic blood perfusion, microcirculation and liver regeneration after major hepatectomy. Thus, cilostazol may represent a novel strategy to reduce the rate of liver failure after both extended hepatectomy and small‐for‐size liver transplantation. This article is protected by copyright. All rights reserved. (Source: Liver Transplantation)
Source: Liver Transplantation - March 1, 2015 Category: Transplant Surgery Authors: Maximilian von Heesen, Stefan Dold, Simon Müller, Claudia Scheuer, Otto Kollmar, Martin K. Schilling, Michael D. Menger, Mohammed R. Moussavian Tags: Original Article Source Type: research
[Prospective, Systematic Observational Study on the Daily Use of Cilostazol (Pletal®) in Clinical Vascular Surgical Practice - Significant Improvement of Walking Distance and Quality of Life for Patients with PAOD, Stage II b.]
Conclusion: Medication with cilostazol led to a significant increase of the maximum walking distance (p < 0.0001) compared to the initial distance, which was further increased through one year (however, the effect became weaker) accompanied by a dominating improvement of the quality of life. The effects can be observed longer than 3-6 months. PMID: 25723863 [PubMed - as supplied by publisher] (Source: Zentralblatt fur Chirurgie)
Source: Zentralblatt fur Chirurgie - February 27, 2015 Category: Surgery Authors: Weber M, Weber T, Meyer F, Halloul Z Tags: Zentralbl Chir Source Type: research
Pletal (Cilostazol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 13, 2015 Category: Drugs & Pharmacology Source Type: news
Wetting Kinetics: an Alternative Approach Towards Understanding the Enhanced Dissolution Rate for Amorphous Solid Dispersion of a Poorly Soluble Drug.
Abstract Developing amorphous solid dispersions of water-insoluble molecules using polymeric materials is a well-defined approach to improve the dissolution rate and bioavailability. While the selected polymer plays a vital role in stabilizing the amorphous solid dispersion physically, it is equally important to improve the dissolution profile by inhibiting crystallization from the supersaturated solution generated by dissolution of the amorphous material. Furthermore, understanding the mechanism of dissolution rate enhancement is of vital importance. In this work, wetting kinetics was taken up as an alternative ap...
Source: AAPS PharmSciTech - February 12, 2015 Category: Drugs & Pharmacology Authors: Verma S, Rudraraju VS Tags: AAPS PharmSciTech Source Type: research
Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products
Abstract Recent studies have demonstrated that the plasma soluble receptor for advanced glycation end-products (sRAGE) play a major role in developing macrovascular complications of type 2 diabetes, including peripheral arterial occlusion disease (PAOD). Cilostazol is an antiplatelet, antithrombotic agent, which has been used for the treatment of PAOD. We hypothesized that cilostazol attenuates the severity of PAOD in patients with type 2 diabetes through the augmentation of plasma sRAGE. Ninety type 2 diabetic patients with PAOD defined as intermittent claudication with ankle-brachial index (ABI) ≦0.9 were recr...
Source: Endocrine - February 10, 2015 Category: Endocrinology Source Type: research
PLETAL (Cilostazol) Tablet [Otsuka America Pharmaceutical, Inc.]
Updated Date: Feb 9, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 9, 2015 Category: Drugs & Pharmacology Source Type: news
Antiplatelet Therapy for Peripheral Arterial Disease and Critical Limb Ischemia: Guidelines Abound, But Where Are the Data?
This article summarizes the major guidelines for antiplatelet therapy, reviews the major studies of antiplatelet therapy in peripheral arterial disease (including data for aspirin, clopidogrel, dipyridamole, cilostazol, and prostanoids), and offers perspective on the potential benefits of ticagrelor, vorapaxar, and rivaroxaban. The review concludes with a discussion of the relative lack of efficacy that antiplatelet therapy has shown in regard to peripheral vascular outcomes. (Source: Journal of Cardiovascular Pharmacology and Therapeutics)
Source: Journal of Cardiovascular Pharmacology and Therapeutics - February 9, 2015 Category: Cardiology Authors: Azarbal, A., Clavijo, L., Gaglia, M. A. Tags: Review Articles Source Type: research
Cilostazol attenuates cholestatic liver injury and its complications in common bile duct ligated rats.
Abstract Cilostazol is a phosphodiesterase III inhibitor increases adenosine 3', 5'-cyclic monophosphate (cyclic AMP) level which inhibits hepatic stellate cell activation. Its pharmacological effects include vasodilation, inhibition of vascular smooth muscle cell growth, inhibition of platelet activation and aggregation. The aim of the current study was to determine the effects of early administration of low dose cilostazol on cholestatic liver injury induced by common bile duct ligation (CBDL) in rat. Male Wistar rats (180-200g) were divided into three groups: Group A; simple laparotomy group (sham). Group B; CBD...
Source: European Journal of Pharmacology - February 6, 2015 Category: Drugs & Pharmacology Authors: Abdel Kawy HS Tags: Eur J Pharmacol Source Type: research
Phosphodiesterase 3 (PDE3) inhibition with Cilostazol does not block in vivo oocyte maturation in rhesus macaques
Studies in mice suggest that cilostazol, an FDA-approved phosphodiesterase 3 (PDE3) inhibitor, might have a contraceptive effect within the approved dose range. We sought to evaluate the potential contraceptive effects of cilostazol in a non-human primate model. (Source: Contraception)
Source: Contraception - January 30, 2015 Category: OBGYN Authors: Carol B. Hanna, Shan Yao, Cathy M. Ramsey, Jon D. Hennebold, Mary B. Zelinski, Jeffrey T. Jensen Tags: Original Research Article Source Type: research
Cilostazol but not sildenafil prevents memory impairment after chronic cerebral hypoperfusion in middle-aged rats.
Abstract We previously reported that the phosphodiesterase-5 (PDE5) inhibitor sildenafil prevented neurodegeneration but not learning deficits in middle-aged rats that were subjected to the permanent, three-stage, four-vessel occlusion/internal carotid artery (4-VO/ICA) model of chronic cerebral hypoperfusion (CCH). In the present study, we examined whether the PDE3 inhibitor cilostazol alleviates the loss of long-term memory (i.e., retrograde amnesia) caused by CCH. The effect of sildenafil was then compared to cilostazol. Naive rats (12-15 months old) were trained in a non-food-rewarded eight-arm radial maze and ...
Source: Behavioural Brain Research - January 23, 2015 Category: Neurology Authors: Godinho J, Oliveira JN, Ferreira ED, Zaghi GG, Bacarin CC, Oliveira RM, Milani H Tags: Behav Brain Res Source Type: research
Neuroprotective effects of cilostazol are mediated by multiple mechanisms in a mouse model of permanent focal ischemia.
Abstract The phosphodiesterase (PDE) 3 inhibitor cilostazol, used as an anti-platelet drug, reportedly can also ameliorate ischemic brain injury. Here, we investigated the effects of cilostazol in a permanent focal ischemia mice model. Male Balb/c mice were subjected to permanent middle cerebral artery occlusion. Mice were then treated with either cilostazol (10 or 20mg/kg) or vehicle administered at 30min and 24h post-ischemia, and infarct volumes were assessed at 48h post-ischemia. Mice treated with 20mg/kg of cilostazol or vehicle were sacrificed at 6h or 24h post-ischemia and immunohistochemistry was used for b...
Source: Brain Research - January 21, 2015 Category: Neurology Authors: Shichinohe H, Tan C, Abumiya T, Nakayama N, Kazumata K, Hokari M, Houkin K, Kuroda S Tags: Brain Res Source Type: research